Predicting Renal, Ophthalmic, And Heart Events In The Aboriginal Community – THE PROPHECY Study
Funder
National Health and Medical Research Council
Funding Amount
$2,574,486.00
Summary
Up to 30% of adult Aboriginal people have diabetes yet our knowledge of the causes and predictors of complications remain incomplete. We have established the PROPHECY Study to assess the levels of complications in Aboriginal people with diabetes; to understand the way that these complications occur, and identify what clinical, social and genetic factors could predict who will get those complications to guide clinical management and prevention.
Clinical Studies Of Diabetes And Tropical Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$568,892.00
Summary
The Fremantle Diabetes Study Phases I and II continue to make important contributions to our understanding of the natural history of diabetes and will be a major focus of the research supported by present application. Studies of malaria and severe bacterial infections in Papua New Guinean children that have regularly contributed to changes in national and regional treatment protocols will also continue under the supervision of the applicant.
Understanding The Early-life Pathways For Adult Type 2 Diabetes Using Existing Data From Seven Cohorts Of The International Childhood Cardiovascular Cohort (i3C) Consortium
Funder
National Health and Medical Research Council
Funding Amount
$336,419.00
Summary
This project will allow us to determine the role that child factors play in the development of diabetes. We will do this using information that has been collected from individuals at several ages extending from childhood to adulthood, somewhat like the “Up” TV series. The project’s findings could lead to improvements in the way we identify people who are at risk of having adult diabetes. By doing so, we could begin programs to stop the young from being struck down by this debilitating disease.
Fenofibrate And Microvascular Events In Type 1 Diabetes (FAME 1) Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,883,529.00
Summary
Diabetes is one of the commonest cause of blindness in adults. Vision loss, which is irreversible, is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate, available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the potential benefits of fenofibrate in 450 adults with Type 1 diabetes who have early diabetic eye damage.
The overall aim is to improve treatments and outcomes for people with osteoporosis. This will be achieved by better predicting those who are likely to fracture and subsequently those who do well post fracture from those who do poorly. Following an osteoporotic fracture there is an increased risk of re- fracture and of premature death. This research will define those risk factors for fracture, re-fracture and early death in a large group of men and women followed for over 20 years.
Defining the molecular and cellular mechanisms of beta cell dysfunction. This project will investigate the influence of environment in the functional adaptation and maladaptation of pancreatic beta cells in diabetes. The research will define the molecular and cellular mechanisms linking environmental triggers such as obesity, high fatty acid levels and hyperglycaemia to beta cell dedifferentiation and dysfunction.